Cytokinetics, Inc. (CYTK)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about Cytokinetics, Inc. (CYTK)

Go deeper and ask any question about CYTK

Company Performance

Current Price

as of Sep 18, 2024

$55.94

P/E Ratio

N/A

Market Cap

$6.58B

Description

Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The firm is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Its clinical-stage drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator, CK-136, a novel cardiac troponin activator, reldesemtiv, a novel fast skeletal muscle troponin activator, aficamten, a novel cardiac myosin inhibitor, and CK-3772271, a novel cardiac myosin inhibitor. The company was founded by Ronald D. Vale, Lawrence S. B. Goldstein, James H. Sabry, and James A. Spudich in 1997 and is headquartered in South San Francisco, CA.

Metrics

Overview

  • HQSouth San Francisco, CA
  • SectorHealth Technology
  • IndustryPharmaceuticals: Major
  • TickerCYTK
  • Price$55.94-0.39%

Trading Information

  • Market Cap$6.58B
  • Float96.67%
  • Average Daily Volume (1m)1,138,505
  • Average Daily Volume (3m)1,406,379
  • EPS-$5.37

Company

  • Revenue$3.13M
  • Rev Growth (1yr)-71.28%
  • Net Income-$143.32M
  • Gross Margin-866.27%
  • EBITDA Margin-51,311.65%
  • EBITDA-$127.77M
  • EV$5.65B
  • EV/Revenue1,803.33
  • P/EN/A
  • P/S1,949.87